Faculty profile

Sachdev Sidhu

ResearcherDonnelly CentreUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.

Sachdev Sidhu

Researcher

Donnelly Centre

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
1 publication in the last five years, latest in 2022.
Principal investigator on 16 research grants (14 CIHR, 2 NSERC), most recently in 2021.
Supervised 5 trainees who won CIHR awards, most recently in 2017.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

212

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Protein Engineering Phage Display Therapeutics Ubiquitin Infectious Diseases Combinatorial Libraries Synthetic Antibodies Coronavirus

Latest papers

Rapid On-Cell Selection of High-Performance Human Antibodies.
ACS central science · 2022
Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2.
Communications biology · 2021
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.
Cell host & microbe · 2020

All 14 publications

Latest funding

COVID-19 Variant Supplement - Rapid development of antiviral compounds to fight the COVID-19 outbreak
CIHR · 2021 · Nominated PI
$50,000
COVID-19 Variant Supplement - Neutralizing Antibodies as SARS-CoV-2 Therapeutics
CIHR · 2021 · Co-investigator
$50,000
Rapid development of antiviral compounds to fight the COVID-19 outbreak
CIHR · 2020 · Nominated PI
$886,090

All 33 grants and awards

14 publications.

Rapid On-Cell Selection of High-Performance Human Antibodies.

Philpott DN, Gomis S, Wang H, Atwal R, Kelil A, Sack T, Morningstar B, Burnie C, Sargent EH, Angers S, Sidhu S, Kelley SO

ACS central science2022

DOI: 10.1021/acscentsci.1c01205 PMID: 35106377

Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2.

Suryamohan K, Diwanji D, Stawiski EW, Gupta R, Miersch S, Liu J, Chen C, Jiang YP, Fellouse FA, Sathirapongsasuti JF, Albers PK, Deepak T, Saberianfar R, Ratan A, Washburn G, Mis M, Santhosh D, Somasekar S, Hiranjith GH, Vargas D, Mohan S, Phalke S, Kuriakose B, Antony A, Ustav M, Schuster SC, Sidhu S, Junutula JR, Jura N, Seshagiri S

Communications biology2021

DOI: 10.1038/s42003-021-02030-3 PMID: 33846513

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.

Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, Bloyet LM, Zeng Q, Tahan S, Droit L, Ilagan MXG, Tartell MA, Amarasinghe G, Henderson JP, Miersch S, Ustav M, Sidhu S, Virgin HW, Wang D, Ding S, Corti D, Theel ES, Fremont DH, Diamond MS, Whelan SPJ

Cell host & microbe2020

DOI: 10.1016/j.chom.2020.06.021 PMID: 32735849

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.

SSRN2020

DOI: 10.2139/ssrn.3606354 PMID: 32714117

Surface Loops in a Single SH2 Domain Are Capable of Encoding the Spectrum of Specificity of the SH2 Family.

Liu H, Huang H, Voss C, Kaneko T, Qin WT, Sidhu S, Li SS

Molecular & cellular proteomics : MCP2019

DOI: 10.1074/mcp.ra118.001123 PMID: 30482845

Co-targeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma.

Qazi MA, Vora P, Venugopal C, Adams J, Singh M, Hu AX, Gorelik M, Subapanditha MK, Savage N, Yang J

Cancer Research201861 citations

DOI: 10.1158/0008-5472.can-18-0267

Syp1 regulates the clathrin-mediated and clathrin-independent endocytosis of multiple cargo proteins through a novel sorting motif.

Apel AR, Hoban K, Chuartzman S, Tonikian R, Sidhu S, Schuldiner M, Wendland B, Prosser D

Molecular biology of the cell2017

DOI: 10.1091/mbc.e15-10-0731 PMID: 28701344

Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.

Steinhart Z, Pavlovic Z, Chandrashekhar M, Hart T, Wang X, Zhang X, Robitaille M, Brown KR, Jaksani S, Overmeer R, Boj SF, Adams J, Pan J, Clevers H, Sidhu S, Moffat J, Angers S

Nature medicine2017

DOI: 10.1038/nm.4219 PMID: 27869803

High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.

Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J

Cell2015

DOI: 10.1016/j.cell.2015.11.015 PMID: 26627737

A High Through-put Platform for Recombinant Antibodies to Folded Proteins.

Hornsby M, Paduch M, Miersch S, Sääf A, Matsuguchi T, Lee B, Wypisniak K, Doak A, King D, Usatyuk S, Perry K, Lu V, Thomas W, Luke J, Goodman J, Hoey RJ, Lai D, Griffin C, Li Z, Vizeacoumar FJ, Dong D, Campbell E, Anderson S, Zhong N, Gräslund S, Koide S, Moffat J, Sidhu S, Kossiakoff A, Wells J

Molecular & cellular proteomics : MCP2015

DOI: 10.1074/mcp.o115.052209 PMID: 26290498

COVID-19 Variant Supplement - Rapid development of antiviral compounds to fight the COVID-19 outbreak

Nominated PICIHR2021Operating Grant: SARS-CoV-2 variants supplement stream 1

Principal investigators: Sidhu, Sachdev S

Keywords: Coronavirus; Deubiquitinase; Displacement Assay; Enzyme Inhibition; Infectious Diseases; Protein Engineering; Small Molecules; Structural Biology; Therapeutics; Ubiquitin

$50,000

COVID-19 Variant Supplement - Neutralizing Antibodies as SARS-CoV-2 Therapeutics

Co-investigatorCIHR2021Operating Grant: SARS-CoV-2 variants supplement stream 1

Principal investigators: Rini, James M

Keywords: Antibodies; Coronavirus; Covid-19; S-Protein; Sars-Cov-2; Therapeutic Antibodies

$50,000

Rapid development of antiviral compounds to fight the COVID-19 outbreak

Nominated PICIHR2020Operating Grant: COVID-19 - Therapeutics

Principal investigators: Sidhu, Sachdev S

Keywords: Coronavirus; Deubiquitinase; Displacement Assay; Enzyme Inhibition; Infectious Diseases; Protein Engineering; Small Molecules; Structural Biology; Therapeutics; Ubiquitin

$886,090

Neutralizing Antibodies as SARS-CoV-2 Therapeutics

Co-investigatorCIHR2020Operating Grant: COVID-19 - Therapeutics

Principal investigators: Rini, James M

Keywords: Antibodies; Coronavirus; Covid-19; S-Protein; Sars-Cov-2; Therapeutic Antibodies

$535,318

Engineering therapeutics for the treatment of anemia in oncology patients

Nominated PICIHR2018Project Grant

Principal investigators: Sidhu, Sachdev S

Keywords: Anemia Management In Oncology; Antibody; Diabody; Erythropoietin; Hormone Mimetic Therapy; Phage Display; Protein Engineering; Protein Variant; Signaling Pathway; Therapeutics

$623,476

Integrated Nanotechnology and Biomedical Sciences Laboratory

Co-investigatorCIHR2017Foundation Grant

Principal investigators: Chan, Warren C

Keywords: Cancer; Nanotechnology

$2,100,092

Sequence signatures in synthetic antibody biophysics

SupervisorCIHR2017Undergraduate: Summer Studentship Award - Institute Community Support

Principal investigators: Ferrari, Daniela

Keywords: Antibodies; Bioinformatics; Combinatorial Libraries; Database; Dna Sequence; Mutation

$5,000

Cancer target discovery and validation in the stromal phospho-proteome

Principal investigatorCIHR2016Project Grant

Principal investigators: Moran, Michael F; Moffat, Jason; Sidhu, Sachdev S

Keywords: Lung Cancer; Phosphorylation

$860,064

Targeting Frizzled proteins in RNF43 mutant cancers.

Principal investigatorCIHR2016Project Grant

Principal investigators: Angers, Stephane; Sidhu, Sachdev S

Keywords: Cancer; Cell Signalling; Colon Cancer; Synthetic Antibodies; Ubiquitin Ligase; Wnt

$1,005,320

Low Cost and Distributed Health Care Applications Based on Cell-free Systems

Co-investigatorCIHR2016Foundation Grant

Principal investigators: Pardee, Keith I

Keywords: Cancer Diagnostics; Drug Resistance Surveillance; Field-Ready Molecular Tools; In Vitro Synthetic Biology; Low Cost And Distributed; Personalized Medicine; Portable Diagnostics; Portable Genotyping; Portable Therapeutic Manufacturing; Protein-Based Therapeutics

$970,555

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Sachdev Sidhu

Research

Latest papers

Latest funding

Rapid On-Cell Selection of High-Performance Human Antibodies.

Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2.

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.

Surface Loops in a Single SH2 Domain Are Capable of Encoding the Spectrum of Specificity of the SH2 Family.

Co-targeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma.

Syp1 regulates the clathrin-mediated and clathrin-independent endocytosis of multiple cargo proteins through a novel sorting motif.

Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.

High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.

A High Through-put Platform for Recombinant Antibodies to Folded Proteins.

COVID-19 Variant Supplement - Rapid development of antiviral compounds to fight the COVID-19 outbreak

COVID-19 Variant Supplement - Neutralizing Antibodies as SARS-CoV-2 Therapeutics

Rapid development of antiviral compounds to fight the COVID-19 outbreak

Neutralizing Antibodies as SARS-CoV-2 Therapeutics

Engineering therapeutics for the treatment of anemia in oncology patients

Integrated Nanotechnology and Biomedical Sciences Laboratory

Sequence signatures in synthetic antibody biophysics

Cancer target discovery and validation in the stromal phospho-proteome

Targeting Frizzled proteins in RNF43 mutant cancers.

Low Cost and Distributed Health Care Applications Based on Cell-free Systems

Frequent collaborators

Jason Moffat

Stephane Angers

Anne Marinier

Ronish Gupta

Parvez Vora

Frank Sicheri

David Kaplan

Daniel Durocher

Daniela Rotin

Sheila Singh

John Parkinson